Arrowhead drug cuts tau levels 73% in early trial data

October 14, 2026 7:30 AM

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported interim Phase 1/2a clinical data for ARO-MAPT, its investigational RNA interference (RNAi) therapy targeting tau ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found